# Fruquintinib Combined With Trastuzumab and XELOX as First-line Treatment in Patients With HER2-positive Advanced Gastric Cancer

> **NCT07334431** · PHASE1,PHASE2 · RECRUITING · sponsor: **Henan Cancer Hospital** · enrollment: 45 (estimated)

## Conditions studied

- Gastric Adenocarcinoma
- Gastric (Stomach) Cancer
- GEJ Adenocarcinoma
- HER2-positive Gastric Cancer
- First-line Therapy
- Fruquintinib

## Interventions

- **DRUG:** fruquintinib＋trastuzumab + XELOX

## Key facts

- **NCT ID:** NCT07334431
- **Lead sponsor:** Henan Cancer Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-02-22
- **Primary completion:** 2025-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 45 (ESTIMATED)
- **Last updated:** 2026-01-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07334431

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07334431, "Fruquintinib Combined With Trastuzumab and XELOX as First-line Treatment in Patients With HER2-positive Advanced Gastric Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07334431. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*